|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Nearly all prostate cancers start out as adenocarcinomas driven by the androgen receptor (AR).
|
31565603 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Androgen deprivation therapy has demonstrated efficacy in cases of salivary duct carcinoma (SDC) and high-grade adenocarcinoma not otherwise specified (NOS) that express androgen receptor.
|
31428578 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These results were supported by human data showing that PEG10 expression is highest in NEPC and that AR-dependent gene, PSA, is negatively correlated with PEG10 in adenocarcinoma.
|
31013476 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Androgen receptor (AR) protein expression is minimal (BMPC1) or absent (BMPC2) consistent with AR loss observed in the BMPC mouse model of invasive adenocarcinoma.
|
29851094 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The molecular networks fueling its emergence and sustenance are still obscure; however, many factors have been associated with the onset and progression of neuroendocrine differentiation in clinically typical adenocarcinomas including loss of androgen-receptor expression and/or signaling, conventional therapy, and dysregulated cytokine function.
|
29981816 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Androgen receptor was positive in 6% of usual-type adenocarcinomas.
|
29851704 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, mixed forms between adenocarcinoma and neuroendocrine prostate cancer (NEPC) have emerged that are characterized by persistent androgen receptor (AR)-signalling and elevated chromogranin A (CgA) levels.
|
30337589 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment-related neuroendocrine prostate cancer transdifferentiates from adenocarcinoma as an adaptive response to androgen receptor pathway inhibition.
|
29396873 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
AIS and adenocarcinoma showed strong expression of a single RTK (EGFR, HER2 or c-Met) on the cell membrane in 41 (77.4%) of 53 cases.
|
28859123 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We detected AR-V7 in just one tumor from men who had undergone prostatectomy for localized adenocarcinoma (n = 30; Gleason 4 + 5 = 9 in the AR-V7-positive sample).
|
27440270 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Only 5 samples were <i>ERG</i>-/AR- corresponding to adenocarcinoma GS of 6.
|
28900498 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
When recurrence was compared among the low-grade group (adenocarcinoma in situ, AIS; minimally invasive adenocarcinoma, MIA), intermediate-grade group (lepidic, acinar, and papillary) and high-grade group (solid and micropapillary), the RFS rate decreased as the grade increased (p = 0.037).
|
28593420 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The co-expression of PHF8 with AR in clinical CRPC samples, normal mouse prostate, and adenocarcinomas of the prostate during PCa progression in a transgenic (TRAMP) mouse model supports the connection between PHF8 and AR.
|
27689328 |
2016 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Genome-wide DNA methylation analysis revealed marked epigenetic differences between CRPC-NE tumors and CRPC-Adeno, and also designated samples of CRPC-Adeno with clinical features of AR independence as CRPC-NE, suggesting that epigenetic modifiers may play a role in the induction and/or maintenance of this treatment-resistant state.
|
26855148 |
2016 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To examine the diversity of somatic alterations and clonal evolution according to aggressiveness of disease, nineteen tumor-blood pairs of 'formerly bronchiolo-alveolar carcinoma (BAC)' which had been reclassified into preinvasive lesion (adenocarcinoma in situ; AIS), focal invasive lesion (minimally invasive adenocarcinoma; MIA), and invasive lesion (lepidic predominant adenocarcinoma; LPA and non-lepidic predominant adenocarcinoma; non-LPA) according to IASLC/ATS/ERS 2011 classification were explored by whole exome sequencing.
|
27545006 |
2016 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The Gleason score was inversely related to the intensity of AR staining in adenocarcinoma.
|
27072221 |
2016 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We molecularly define transition stages from PIN lesions to hyperplasia/neoplasia and progression to adenocarcinoma by temporal changes in expression of human prostate cancer markers, including the androgen receptor and tumor suppressors, Nkx3.1 and PTEN.
|
27634876 |
2016 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Such neoplasms seldom occurred in parental TRAMP mice otherwise prone to adenocarcinomas and were characterized for being androgen receptor negative, highly proliferative and endowed with neuroendocrine (NE) features.
|
26700622 |
2016 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We found a strong lineage relationship between the majority of adjacent lepidic and invasive components, supporting a putative AIS-AD transition.
|
24879567 |
2014 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The objective was to characterize and associate the receptor reactivities of fibroblastic growth factor (FGF)-2, FGF-7, FGF-8, epidermal growth factor (EGF), α-actin and vimentin in relation to the androgen receptor (AR), α and β estrogen receptors (ERα and ERβ), and prolactin receptor in the prostate of elderly men showing low- and high-grade adenocarcinoma.
|
23362007 |
2013 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, AR protein levels were determined in a cohort of 73 Grade III invasive breast ductal adenocarcinomas.
|
22471922 |
2012 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The majority of the prostatic cancers are adenocarcinomas characterized by glandular formation and the expression of luminal differentiation markers androgen receptor (AR) and prostate-specific antigen (PSA).
|
21432867 |
2011 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Dietary SSA consumption dramatically attenuated prostatic growth and suppressed AR-dependent glandular epithelial lesion progression through repressing cell proliferation in the transgenic adenocarcinoma of mouse prostate mice, whereas it did not significantly affect neuroendocrine carcinoma growth.
|
20587701 |
2010 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Forced expression of FASN in iPrECs, AR-iPrECs, and LNCaP cells increased cell proliferation and soft agar growth. iPrECs that expressed both FASN and androgen receptor (AR) formed invasive adenocarcinomas in immunodeficient mice (12 of 14 mice injected formed tumors vs 0 of 14 mice injected with AR-iPrEC expressing empty vector (P < .001, Fisher exact test); however, iPrECs that expressed only FASN did not.
|
19318631 |
2009 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Most prostate adenocarcinomas expressed a range of levels of C/EBPalpha mRNA and protein that were relatively high in metastatic tumors in a manner that correlated with AR expression; however, most cells showed C/EBPalpha sequestered in the cytosol.
|
18481268 |
2008 |